NO332776B1 - Nasal farmasoytisk sammensetning av piribedil - Google Patents
Nasal farmasoytisk sammensetning av piribedil Download PDFInfo
- Publication number
- NO332776B1 NO332776B1 NO20060743A NO20060743A NO332776B1 NO 332776 B1 NO332776 B1 NO 332776B1 NO 20060743 A NO20060743 A NO 20060743A NO 20060743 A NO20060743 A NO 20060743A NO 332776 B1 NO332776 B1 NO 332776B1
- Authority
- NO
- Norway
- Prior art keywords
- piribedil
- pharmaceutical composition
- cyclodextrin
- amount
- composition according
- Prior art date
Links
- 229960004310 piribedil Drugs 0.000 title claims abstract description 30
- OQDPVLVUJFGPGQ-UHFFFAOYSA-N 2-[4-(1,3-benzodioxol-5-ylmethyl)-1-piperazinyl]pyrimidine Chemical group C=1C=C2OCOC2=CC=1CN(CC1)CCN1C1=NC=CC=N1 OQDPVLVUJFGPGQ-UHFFFAOYSA-N 0.000 title claims abstract description 29
- 239000008194 pharmaceutical composition Substances 0.000 title claims abstract description 24
- 239000000843 powder Substances 0.000 claims abstract description 11
- 229920000858 Cyclodextrin Polymers 0.000 claims description 19
- HFHDHCJBZVLPGP-UHFFFAOYSA-N schardinger α-dextrin Chemical compound O1C(C(C2O)O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC(C(O)C2O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC2C(O)C(O)C1OC2CO HFHDHCJBZVLPGP-UHFFFAOYSA-N 0.000 claims description 12
- 239000000203 mixture Substances 0.000 claims description 9
- 239000007864 aqueous solution Substances 0.000 claims description 7
- 150000003839 salts Chemical class 0.000 claims description 3
- 125000002496 methyl group Chemical class [H]C([H])([H])* 0.000 claims description 2
- 239000000546 pharmaceutical excipient Substances 0.000 claims description 2
- 238000006467 substitution reaction Methods 0.000 claims description 2
- 238000009472 formulation Methods 0.000 description 8
- 229940097362 cyclodextrins Drugs 0.000 description 7
- 239000000243 solution Substances 0.000 description 7
- 239000007921 spray Substances 0.000 description 4
- 238000013265 extended release Methods 0.000 description 3
- 229940098458 powder spray Drugs 0.000 description 3
- 230000001225 therapeutic effect Effects 0.000 description 3
- 200000000007 Arterial disease Diseases 0.000 description 2
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 2
- 208000018737 Parkinson disease Diseases 0.000 description 2
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 2
- 238000010521 absorption reaction Methods 0.000 description 2
- 239000004480 active ingredient Substances 0.000 description 2
- 230000001684 chronic effect Effects 0.000 description 2
- NZAQRZWBQUIBSF-UHFFFAOYSA-N 4-(4-sulfobutoxy)butane-1-sulfonic acid Chemical compound OS(=O)(=O)CCCCOCCCCS(O)(=O)=O NZAQRZWBQUIBSF-UHFFFAOYSA-N 0.000 description 1
- 206010001541 Akinesia Diseases 0.000 description 1
- 206010010904 Convulsion Diseases 0.000 description 1
- 102000015554 Dopamine receptor Human genes 0.000 description 1
- 108050004812 Dopamine receptor Proteins 0.000 description 1
- 206010022562 Intermittent claudication Diseases 0.000 description 1
- 206010044565 Tremor Diseases 0.000 description 1
- 230000001154 acute effect Effects 0.000 description 1
- 230000002490 cerebral effect Effects 0.000 description 1
- 230000001149 cognitive effect Effects 0.000 description 1
- 230000006735 deficit Effects 0.000 description 1
- 239000003136 dopamine receptor stimulating agent Substances 0.000 description 1
- 230000003291 dopaminomimetic effect Effects 0.000 description 1
- 239000011521 glass Substances 0.000 description 1
- -1 hydroxypropyl Chemical group 0.000 description 1
- 208000021156 intermittent vascular claudication Diseases 0.000 description 1
- 230000000302 ischemic effect Effects 0.000 description 1
- 238000010983 kinetics study Methods 0.000 description 1
- 230000002045 lasting effect Effects 0.000 description 1
- 210000003141 lower extremity Anatomy 0.000 description 1
- 210000002850 nasal mucosa Anatomy 0.000 description 1
- 230000001575 pathological effect Effects 0.000 description 1
- 230000037361 pathway Effects 0.000 description 1
- 230000002093 peripheral effect Effects 0.000 description 1
- 230000036470 plasma concentration Effects 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- 238000001356 surgical procedure Methods 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0043—Nose
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/08—Vasodilators for multiple indications
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
- General Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Otolaryngology (AREA)
- Heart & Thoracic Surgery (AREA)
- Psychology (AREA)
- Hospice & Palliative Care (AREA)
- Psychiatry (AREA)
- Cardiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| FR0308712A FR2857594B1 (fr) | 2003-07-17 | 2003-07-17 | Composition pharmaceutique pour l'administration par voie nasale de piribedil |
| PCT/FR2004/001867 WO2005009442A1 (fr) | 2003-07-17 | 2004-07-16 | Composition pharmaceutique pour l’administration par voie nasale de piribedil |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| NO20060743L NO20060743L (no) | 2006-02-16 |
| NO332776B1 true NO332776B1 (no) | 2013-01-14 |
Family
ID=33548200
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| NO20060743A NO332776B1 (no) | 2003-07-17 | 2006-02-16 | Nasal farmasoytisk sammensetning av piribedil |
Country Status (29)
| Country | Link |
|---|---|
| US (1) | US20060204449A1 (es) |
| EP (1) | EP1653963B1 (es) |
| JP (1) | JP2007516947A (es) |
| KR (1) | KR100807480B1 (es) |
| CN (1) | CN100540004C (es) |
| AR (1) | AR046808A1 (es) |
| AT (1) | ATE349213T1 (es) |
| AU (1) | AU2004258714A1 (es) |
| BR (1) | BRPI0412681A (es) |
| CA (1) | CA2532631C (es) |
| CY (1) | CY1106013T1 (es) |
| DE (1) | DE602004003955T2 (es) |
| DK (1) | DK1653963T3 (es) |
| EA (1) | EA011041B1 (es) |
| ES (1) | ES2279435T3 (es) |
| FR (1) | FR2857594B1 (es) |
| GE (1) | GEP20074259B (es) |
| HR (1) | HRP20070081T5 (es) |
| MA (1) | MA27864A1 (es) |
| MX (1) | MXPA06000641A (es) |
| MY (1) | MY137747A (es) |
| NO (1) | NO332776B1 (es) |
| NZ (1) | NZ544460A (es) |
| PL (1) | PL1653963T3 (es) |
| PT (1) | PT1653963E (es) |
| SI (1) | SI1653963T1 (es) |
| UA (1) | UA85193C2 (es) |
| WO (1) | WO2005009442A1 (es) |
| ZA (1) | ZA200600240B (es) |
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| NO2303330T3 (es) * | 2008-06-06 | 2018-04-14 | ||
| CN105163729A (zh) * | 2013-03-13 | 2015-12-16 | N到B有限公司 | 用于治疗与帕金森氏病相关的运动和抑郁症状的方法、组合物和装置 |
| IT201800005117A1 (it) | 2018-05-07 | 2019-11-07 | Acqua irradiata con energie elettromagnetiche per uso terapeutico |
Family Cites Families (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| BE1007402A5 (nl) * | 1993-03-26 | 1995-06-06 | Adir | Nasale farmaceutische preparaten met progestagene stof. |
| ATE241984T1 (de) * | 1993-03-26 | 2003-06-15 | Franciscus Wilhelmus He Merkus | Pharmazeutische zusammensetzungen zur intranasalen verabreichung von apomorphin |
| FR2710268B1 (fr) * | 1993-09-22 | 1995-10-20 | Adir | Utilisation de beta-cyclodextrines partiellement méthylées comme promoteurs d'absorption dans la préparation de compositions pharmaceutiques pour l'administration transcutanée de principes actifs. |
| FR2710265B1 (fr) * | 1993-09-22 | 1995-10-20 | Adir | Composition pharmaceutique bioadhésive pour la libération contrôlée de principes actifs. |
| FR2742989B1 (fr) * | 1995-12-29 | 1998-01-23 | Adir | Composition pharmaceutique bioadhesive pour la liberation controlee de principes actifs |
| JP2001518923A (ja) * | 1997-03-26 | 2001-10-16 | ダブリュ エイチ エム マーカス，フランシスカス | 鼻腔用メラトニン組成物 |
| EP0900567A3 (en) * | 1997-09-05 | 2001-05-02 | Pfizer Products Inc. | Quinazoline-4-one AMPA antagonists for the treatment of dyskinesias associated with dopamine agonist therapy |
| US20020002175A1 (en) * | 2000-09-19 | 2002-01-03 | Charanjit Behl | Nasal delivery of apomorphine in combination with glycol derivatives |
| US20040028613A1 (en) * | 2001-06-25 | 2004-02-12 | Nastech Pharmaceutical Company Inc | Dopamine agonist formulations for enhanced central nervous system delivery |
| FR2827516B1 (fr) * | 2001-07-19 | 2003-09-19 | Servier Lab | Composition pharmaceutique pour l'administration par voie nasale d'estradiol et de norethisterone |
-
2003
- 2003-07-17 FR FR0308712A patent/FR2857594B1/fr not_active Expired - Fee Related
-
2004
- 2004-07-15 MY MYPI20042838A patent/MY137747A/en unknown
- 2004-07-15 AR ARP040102489A patent/AR046808A1/es unknown
- 2004-07-16 AT AT04767691T patent/ATE349213T1/de active
- 2004-07-16 MX MXPA06000641A patent/MXPA06000641A/es active IP Right Grant
- 2004-07-16 GE GEAP20049239A patent/GEP20074259B/en unknown
- 2004-07-16 HR HR20070081T patent/HRP20070081T5/xx unknown
- 2004-07-16 ES ES04767691T patent/ES2279435T3/es not_active Expired - Lifetime
- 2004-07-16 AU AU2004258714A patent/AU2004258714A1/en not_active Abandoned
- 2004-07-16 UA UAA200601630A patent/UA85193C2/ru unknown
- 2004-07-16 BR BRPI0412681-5A patent/BRPI0412681A/pt not_active IP Right Cessation
- 2004-07-16 ZA ZA200600240A patent/ZA200600240B/en unknown
- 2004-07-16 PL PL04767691T patent/PL1653963T3/pl unknown
- 2004-07-16 DK DK04767691T patent/DK1653963T3/da active
- 2004-07-16 CN CNB2004800197495A patent/CN100540004C/zh not_active Expired - Fee Related
- 2004-07-16 WO PCT/FR2004/001867 patent/WO2005009442A1/fr not_active Ceased
- 2004-07-16 PT PT04767691T patent/PT1653963E/pt unknown
- 2004-07-16 DE DE602004003955T patent/DE602004003955T2/de not_active Expired - Lifetime
- 2004-07-16 JP JP2006519966A patent/JP2007516947A/ja active Pending
- 2004-07-16 KR KR1020067001141A patent/KR100807480B1/ko not_active Expired - Fee Related
- 2004-07-16 NZ NZ544460A patent/NZ544460A/en not_active IP Right Cessation
- 2004-07-16 SI SI200430163T patent/SI1653963T1/sl unknown
- 2004-07-16 US US10/564,139 patent/US20060204449A1/en not_active Abandoned
- 2004-07-16 CA CA2532631A patent/CA2532631C/fr not_active Expired - Fee Related
- 2004-07-16 EP EP04767691A patent/EP1653963B1/fr not_active Expired - Lifetime
- 2004-07-16 EA EA200600172A patent/EA011041B1/ru not_active IP Right Cessation
-
2005
- 2005-12-27 MA MA28688A patent/MA27864A1/fr unknown
-
2006
- 2006-02-16 NO NO20060743A patent/NO332776B1/no not_active IP Right Cessation
-
2007
- 2007-02-13 CY CY20071100190T patent/CY1106013T1/el unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2019131596A5 (es) | ||
| EA200800798A1 (ru) | Фармацевтические композиции, предназначенные для лечения нарушений внутреннего уха | |
| JP7418475B2 (ja) | バイオフィルムが関与する細菌感染症を治療するための医薬及びその使用 | |
| DE60121301D1 (de) | Flibanserin zur Behandlung extrapyramidaler Bewegungsstörungen | |
| JP2012522783A5 (es) | ||
| BR112012030641B8 (pt) | Usos e composições para terapia farmacêutica oral | |
| JP6196704B2 (ja) | 神経因性疾病の治療のための医薬 | |
| TWI565470B (zh) | 玻尿酸之用途及疼痛抑制用醫藥組成物 | |
| JP2014508758A5 (es) | ||
| KR20200049697A (ko) | 인 시추 겔-형성 약제학적 조성물 및 부비동 질병에 있어서 이의 용도 | |
| WO2017192744A1 (en) | Systems and methods for treating bacterial infection | |
| JP2009507048A5 (es) | ||
| NO332776B1 (no) | Nasal farmasoytisk sammensetning av piribedil | |
| JP6255134B1 (ja) | 耳炎の治療のための組成物および方法 | |
| RU2012107483A (ru) | Отамиксабан для лечения инфаркта миокарда без подъема сегмента st у пациентов пожилого возраста и пациентов с нарушенной функцией почек | |
| ES2447829T3 (es) | Combinación para el tratamiento de la osteoartritis | |
| HK1094153B (en) | Nasal pharmaceutical composition of piribedil | |
| CN102008470A (zh) | 复方制剂及其预防和治疗噪声性听力损伤的用途 | |
| ES2263959T3 (es) | Composicion farmaceutica de piribedil bucodispersable. | |
| UA112652C2 (uk) | Фармацевтична композиція для лікування передчасної еякуляції і спосіб лікування передчасної еякуляції | |
| CN101574333A (zh) | 一种大蒜新素组合物及在其制备治疗鼻腔微生物感染中的滴剂的方法和应用 | |
| JP2008520607A5 (es) | ||
| ES2749128T3 (es) | Composición para el tratamiento de rinitis |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| MM1K | Lapsed by not paying the annual fees |